RxDoctor Payments DataLook up a doctor →

Nirav Shah, MD

Gastroenterology · Wyomissing, PANPI 1023148731

Payments from drug & device makers

$3,465,502in general payments, 2019–2025

Across 469 payments — averaging $7389.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2.9M
  • GSK$241K
  • AbbVie$164K
  • Boehringer Ingelheim International GmbH$41K
  • Medtronic$22K
  • Takeda Pharmaceuticals U.S.A., Inc.$22K
  • plus $88K from 38 others
$4,001in research payments, 2019–2025

Across 7 payments — averaging $571.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$4K

What the payments were for

  • Consulting fees$34,20466%
  • Speaking & faculty fees$8,66317%
  • Travel & lodging$4,1988%
  • Food & beverage$4,8599%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,465,502 in reported general payments places this provider in the 95th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$167,382
Medicare patients
456
Services billed
3,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid12$110,589
CreonLipase/Protease/Amylase15$43,420
LinzessLinaclotide22$20,962
Mesalamine11$14,748
Dexlansoprazole DrDexlansoprazole14$4,224
Omeprazole241$3,691
Esomeprazole Magnesium34$3,558
Pantoprazole Sodium130$1,998
Lubiprostone12$1,053
Lansoprazole12$817
Famotidine12$105
Ciprofloxacin Hcl11$17

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$145$110,58912 claims
AbbVieCreon, Linzess$163,937$64,38237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →